


 **BD BACTEC™**
MGIT™ II 960



BD BACTEC™ MGIT™ II System

Setting the standard for today's
Tuberculosis (TB) culture diagnostics



Tuberculosis is the world's leading infectious killer.¹

1.23M

TB-related deaths globally in 2024¹

12%*

reduction in global TB incidence rate from 2015 to 2024¹

83M

lives saved since 2000 through TB diagnosis and treatment¹



For TB diagnosis, culture testing remains the reference standard.³

While molecular testing is fast, it does not replace culture or growth-based drug susceptibility testing (DST).⁴

The World Health Organization (WHO) recognizes that liquid and solid phenotypic DST, including the Mycobacterial Growth Indicator Tube (MGIT) system, is both reliable and reproducible; and acts as a reference standard for many anti-TB medicines.⁵

~400k

new multidrug resistant/
rifampin resistant TB cases in 2023²

Delivering results clinicians can trust

Faced with rising demand for TB culture testing and the evolving complexity of drug resistance, labs must be prepared to handle what comes next.

*falling short of the 80% reduction milestone by 2030 outlined in WHO's End TB strategy

Built on decades at the forefront of TB testing

The updated BD BACTEC™ MGIT™ II system modernizes automated TB culture testing to help improve operational efficiency, strengthen cybersecurity and data integrity. It enables future workflow expansion while maintaining the trusted MGIT phenotypic workflow relied upon by labs around the world.



Moving forward on strong foundations

Based on the recognized MGIT phenotypic testing workflow, our latest system retains continuity at its core



Phenotypic TB testing and DST

Culture-based growth and first-line susceptibility testing remain central to MGIT testing pathway



Core workflow

Specimen processing, MGIT tube preparation, scan/load, growth detection and reporting




Consistent Consumables

The system is designed to use the same consumables, BD BACTEC™ MGIT™ tubes and DST kits



Informatics continuity

Analysis and reporting remain supported by BD Epicenter™ data management



Modular configurations

320 and 960 tube capacity models support scalable lab volumes

Where pace meets predictability

Streamline TB culture workflows and reduce user variability

BD BACTEC™ MGIT™ II system is designed for today's TB labs, combining reliable performance and intuitive usability to help streamline daily culture testing operations. Remote service support enables fast software troubleshooting and accelerated service triage, helping minimize downtime and maintain operational continuity.

1M+

sample runs
analyzed⁶

Supports high
volume TB testing
with confidence

61,800+

hours of operational
testing⁶

Reliability tested
beyond routine lab
demand



Efficiency on display

Modern 10.4-inch color touchscreen
with intuitive navigation, clear on-screen
guidance and fewer touchpoints to help
streamline workflows, reduce complexity
and improve workflow visibility.



Review data on demand

Operations

Tube Entry, Remove positive, Identify anonymous, Remove ongoing, Resolve station error, Remove negative, Remove Complete AST set

Summary

	A	B	C
Positive	0	0	0
Negative	0	0	0
Ongoing	0	0	0
Anonymous	3	0	0
Error	0	0	0
Blocked	0	0	0
Empty	317	320	320

Antimicrobial Susceptibility Testing (AST)

Reports

Anonymization: ☐ Enable ☒ Disable

Unloaded positive tubes, Unloaded negative tubes, Unloaded ongoing tubes, Unloaded AST sets, QC reports, Instrument inventory

EXIT

On-screen access to in-progress, historical reports and date-range report retrieval help labs review test data with optimal efficiency.

User-friendly features

From initial loading to reviewing results, new users found the BD BACTEC™ MGIT™ II system easy to use from start to finish

92%

users found the instrument easy to use⁷

Modern touchscreen helps streamline activities

98%

users found tube loading easy⁷

Simpler loading helps reduce touchpoints and keeps testing moving

100%

users were able to review report results without assistance⁷

Supports efficient access to results

Guarding against new threats

BD BACTEC™ MGIT™ II system has been designed to help strengthen cybersecurity measures and protect the integrity of critical TB culture data

- **Built on modern Windows® IOT 10 secure system architecture with encryption at rest**, role-based user authentication, and built-in anti-malware protection to help labs protect critical TB culture data against cyber threats and support traceability.
- **Expanded storage (512GB)** reduces risk of data loss.
- **Historical report access** helps support audit and compliance readiness.



 **BD BACTEC™ MGIT™ II**


Screen is locked
To unlock the screen, press and hold "UNLOCK" button.

UNLOCK

 11/7/2025 4:16 AM 

From Date  To Date  

BD BACTEC™ MGIT™ II 960
Unloaded Positives Report

Instrument Number	Current Date/Time	Temperature			Software Version	Page Number		
		A	B	C				
1	11/7/2025 4:16 AM	37.80 C	37.80 C	37.77 C	V1.00.07	1 of 1		
Tube Position	Accession number	Sequence Number	Growth Unit	Tube Status	TTD	Date Positive	Protocol Length	Start Of Protocol
A/C08	430197468617	0	+T	0-4	11/06/25	1	11/06/25 02:11	




Enabling your workflow to grow



Enable Future Workflow Expansion

BD BACTEC™ MGIT™ II enables future workflow expansion and integration through a modernized system foundation with sustained parts availability, remote service support capabilities, USB-compatible printing and software readiness for future connectivity.





References

1. Global TB report 2025 *Global tuberculosis report 2025*
2. CDC 2025_DGHT-TB-Overview-Factsheet.pdf
3. Bartolomeu-Gonçalves et.al., 2024, *Tuberculosis Diagnosis: Current, Ongoing and future approached* <https://doi.org/10.3390/diseases12090202>
4. CDC Xpert MTB/RIF guidance- Xpert MTB/RIF Assay I Tuberculosis (TB) I CDC
5. WHO TB handbook 2.5 Phenotypic and genotypic drug resistance testing methods I TB Knowledge Sharing
6. Reliability Growth test summary report VP-11946-01-10267.
7. BD BACTEC™ MGIT II System, *Human Factors/Useability Engineering Validation Test Report*, Dir. No: SUMR-20260130 Ver 01.

Disclaimer: This business has been acquired by Waters Corporation ("Waters"). Becton, Dickinson and Company or one of its affiliates or subsidiaries ("BD") remains the legal manufacturer of Biosciences and Diagnostic Solutions products until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under BD's regulatory authority. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary: www.waters.com/bdtransaction.

BD Diagnostics, 7 Loveton Circle, Sparks, MD 21152-0999 U.S.
800.638.8663

bd.com

